High-Precision Affinity Measurement Services

Q: What is the difference between affinity (KD) and avidity?

Affinity (KD) refers to the strength of a single, monovalent interaction between one binding site on a molecule and its partner (e.g., a single Fab arm of an IgG binding to its epitope). Avidity describes the overall, combined strength of multiple, simultaneous interactions (e.g., a bivalent IgG binding with both of its Fab arms to two antigens on a cell surface). Avidity is often much stronger than the intrinsic affinity of the individual interactions. Our platforms can be configured to measure both. Standard assays typically measure affinity, but we can design specific assays to characterize the avidity of multivalent interactions.

Q: Why is off-rate (kd) considered so important in drug development?

The off-rate (kd, or dissociation rate) measures how quickly a drug dissociates from its target. A slow off-rate indicates a long residence time of the drug on its target, which often correlates with prolonged pharmacological effects and higher in vivo potency. For many therapeutic antibodies, a slow off-rate is a key selection criterion, as it can lead to more durable target engagement and potentially less frequent dosing. Our affinity measurement services provide precise off-rate data to help you rank and select the most promising candidates.

Background Platform Comparison Workflow Feature Related Services FAQ Online Inquiry

In the landscape of therapeutic drug development, a deep understanding of molecular interactions is paramount. The affinity of an antibody for its antigen is a critical quality attribute (CQA) that dictates its potency, specificity, and overall therapeutic efficacy. At Creative Biolabs, we provide a comprehensive suite of affinity measurement services, leveraging state-of-the-art technologies to deliver high-precision, reliable, and insightful data for your research, preclinical, and clinical programs. Our two decades of experience are built on a foundation of scientific excellence and a commitment to helping our clients accelerate their discovery and development pipelines. We specialize in label-free, real-time analysis of biomolecular interactions, providing you with the critical kinetic data (k_a, k_d) and affinity constants (K_D) needed to make informed decisions, de-risk candidates, and satisfy regulatory requirements.

Discuss Your Project Today

The Central Role of Affinity in Drug Discovery

Binding affinity, quantified by the equilibrium dissociation constant (K_D), is the measure of the strength of the non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and its ligand (e.g., an antigen).

Where:

k_a (Association Rate Constant): The rate at which the antibody binds to its antigen.
k_d (Dissociation Rate Constant): The rate at which the antibody-antigen complex falls apart.
K_D (Equilibrium Dissociation Constant): The concentration of ligand at which half of the binding sites of the antibody are occupied at equilibrium. A lower K_D value signifies a higher binding affinity.

Understanding these parameters is crucial for:

Candidate Selection and Optimization: Ranking and selecting lead candidates with the desired affinity profile.
Mechanism of Action (MoA) Studies: Elucidating how a drug engages its target.
Structure-Activity Relationship (SAR) Analysis: Guiding protein engineering and optimization efforts.
Quality Control (QC): Ensuring batch-to-batch consistency and product stability.
Competitive Analysis: Comparing the binding properties of a biosimilar to a reference product.
Epitope Binning: Determining if different antibodies bind to overlapping epitopes on an antigen.

Our Premier Affinity Measurement Platforms

Creative Biolabs has invested in a diverse range of cutting-edge platforms to offer you unparalleled flexibility and accuracy. Our core technologies, Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI), are the gold standards for label-free interaction analysis.

Surface Plasmon Resonance (SPR) – Unrivaled Sensitivity and Precision

SPR is a powerful optical technique that measures changes in the refractive index at the surface of a sensor chip. It provides real-time, high-quality kinetic and affinity data, making it the preferred method for a wide range of applications, from early-stage screening to in-depth characterization.

Our SPR capabilities are powered by industry-leading instruments

Biacore Systems: Renowned for their high sensitivity and precision, Biacore platforms are ideal for detailed kinetic characterization, low molecular weight (LMW) fragment screening, and analyzing complex interactions.
ProteOn XPR36 System: This system offers a unique 6x6 interaction array, enabling the analysis of up to 36 different interactions simultaneously. This makes it highly efficient for screening and epitope binning studies.

Fig. 1 Surface Plasmon Resonance Principle and Instrumentation. (Creative Biolabs Authorized) Fig. 1 Principle and Instrumentation of Surface Plasmon Resonance.

Key Applications of Our SPR Services

Application	Description
Full Kinetic Profiling	Precise determination of k_a, k_d, and K_D for in-depth candidate characterization.
High-Throughput Screening	Rapid screening of antibody libraries or hybridoma supernatants to rank candidates by off-rate.
Small Molecule Analysis	High-sensitivity detection of interactions between proteins and small molecules or fragments.
Epitope Binning & Mapping	Comprehensive analysis to group antibodies based on their binding epitopes.
Thermodynamic Analysis	Measuring binding at different temperatures to understand the thermodynamic drivers of the interaction.
Concentration Analysis	Accurate, label-free quantification of active protein concentration.

Bio-Layer Interferometry (BLI) – Speed, Throughput, and Versatility

BLI is an optical analytical technique that measures the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip and an internal reference layer. Binding of analyte to the biosensor tip causes a wavelength shift in the interference pattern, which is monitored in real-time.

Our primary BLI platform is the Octet® System, which offers significant advantages

Fluidics-Free Operation: The "dip-and-read" format is robust, easy to use, and compatible with crude or complex samples like lysates and supernatants.
High Throughput: With the ability to analyze 8 or 16 samples in parallel, the Octet platform is ideal for screening large numbers of samples quickly.
Sample Conservation: The sample can be recovered and used for other assays after the analysis.

Key Applications of Our BLI Services

Application	Description
Rapid Affinity Screening	Ideal for early-stage discovery, enabling high-throughput ranking of hundreds of clones.
Quantitation	Fast and accurate measurement of protein concentration (e.g., IgG titer) from crude samples.
Fc Receptor Binding	Characterizing the interaction of antibodies with Fc receptors (FcγR, FcRn) to predict effector function and half-life.
Batch Release & QC	A quick and reliable method for ensuring the binding activity of manufactured lots.
Yes/No Binding Analysis	Quickly confirming the presence or absence of a specific binding interaction.

Choosing the Right Platform: SPR vs. BLI

The choice between SPR and BLI depends on your specific application, sample type, and stage of research. Our experts will work closely with you to select the most appropriate technology for your project.

Feature	Surface Plasmon Resonance (SPR)	Bio-Layer Interferometry (BLI)
Principle	Refractive index change	Interference pattern shift
Sensitivity	Very High (ideal for small molecules)	High (better for larger molecules)
Throughput	Medium to High	High to Very High
Fluidics	Microfluidics-based	Fluidics-free (dip-and-read)
Sample Type	Requires purified samples	Tolerant of crude/complex samples
Sample Recovery	Not possible	Yes
Primary Use Cases	Detailed kinetics, small molecules, thermodynamics	High-throughput screening, quantitation, QC

A Comprehensive Workflow for Your Affinity Measurement Project

At Creative Biolabs, we follow a rigorous and transparent process to ensure the highest quality data and client satisfaction.

Consultation and Project Design: We begin with a detailed discussion to understand your project goals, molecules, and desired outcomes. Our scientists will recommend the optimal platform and experimental design.
Assay Development and Optimization: We meticulously optimize assay conditions, including ligand immobilization strategy, buffer selection, and analyte concentration series, to ensure robust and reliable data.
Sample Analysis: Your samples are run on our state-of-the-art Biacore, ProteOn, or Octet systems by our highly trained technicians.
Data Processing and Analysis: Raw data is processed using advanced software to perform reference subtraction, curve fitting, and calculation of kinetic and affinity constants.
Comprehensive Reporting: You will receive a detailed report containing all methods, raw data, processed sensorgrams, and a clear summary of the results and conclusions. Our scientists are always available to discuss the results and next steps.

Beyond Standard Affinity Measurement

Creative Biolabs offers a range of specialized services to address more complex biological questions:

Affinity Measurement for Membrane Proteins: We have developed proprietary techniques for analyzing interactions involving challenging targets like GPCRs and ion channels, using nanodiscs, liposomes, or virus-like particles (VLPs).
Affinity of Bispecific Antibodies and ADCs: We can design multi-step assays to characterize the binding of each arm of a bispecific antibody or assess how conjugation affects the affinity of an antibody-drug conjugate (ADC).
Small Molecule and Fragment-Based Screening: Our high-sensitivity SPR platforms are perfectly suited for fragment-based drug discovery (FBDD) campaigns.

Partner with the Experts in Biomolecular Interaction Analysis

Leverage our integrated service portfolio to support every stage of your antibody development program.

Antibody Affinity Maturation Services: Enhance the potency of your lead candidates with our proven affinity maturation strategies.
Custom Antibody Production: From discovery to large-scale manufacturing, we provide high-quality recombinant and hybridoma-based antibody production.
De Novo Antibody Sequencing: Determine the exact sequence of your monoclonal antibodies with 100% accuracy.
Antibody Functional Assays: Go beyond binding and evaluate the biological impact of your antibody with our cell-based and functional assay services.
Epitope Mapping Services: Pinpoint the precise binding site of your antibody on its target antigen.

Other optional Affinity Measurement Services:

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: What is the typical sample requirement for an affinity measurement project?

A: Sample requirements vary depending on the platform and the nature of the molecules. As a general guideline:

For SPR (Biacore, ProteOn): We typically require 50-100 µg of purified analyte and 20-50 µg of purified ligand. For small molecule analytes, we may require a higher concentration.
For BLI (Octet): We recommend providing at least 100 µL of analyte at a concentration 10-20 times higher than the expected K_D. For the ligand to be immobilized on the biosensor, 20-50 µg is usually sufficient.

We will provide you with specific recommendations during the project design phase.

Q: Can you measure the affinity of unpurified samples?

A: Yes. Our BLI (Octet) platform is exceptionally well-suited for analyzing crude samples. Its fluidics-free, dip-and-read format is tolerant of complex matrices, allowing us to directly measure protein concentration or binding kinetics from hybridoma supernatants, cell lysates, or periplasmic extracts. This saves you valuable time and resources by eliminating the need for upfront purification, especially during early-stage screening.

Q: How do you choose the right immobilization strategy for my ligand?

A: The choice of immobilization strategy is critical for obtaining high-quality data. Our scientists consider several factors, including the nature of your ligand (e.g., protein, antibody, peptide), available functional groups, and the need to maintain its native conformation. Common strategies include:

Amine Coupling: The most common method, coupling to primary amines (lysine residues).
Capture-Based Methods: Using anti-Fc, anti-His, Protein A, or Protein G surfaces to orient antibodies or tagged proteins uniformly.
Thiol Coupling: For proteins or peptides with available cysteine residues.
Biotin-Streptavidin: A high-affinity capture method for biotinylated ligands.

We will always select the strategy that ensures the highest activity and stability of your immobilized molecule.

Q: What is the difference between affinity (K_D) and avidity?

A: Affinity (K_D) refers to the strength of a single, monovalent interaction between one binding site on a molecule and its partner (e.g., a single Fab arm of an IgG binding to its epitope).

Avidity describes the overall, combined strength of multiple, simultaneous interactions (e.g., a bivalent IgG binding with both of its Fab arms to two antigens on a cell surface). Avidity is often much stronger than the intrinsic affinity of the individual interactions.

Our platforms can be configured to measure both. Standard assays typically measure affinity, but we can design specific assays to characterize the avidity of multivalent interactions.

Q: Why is off-rate (k_d) considered so important in drug development?

A: The off-rate (k_d, or dissociation rate) measures how quickly a drug dissociates from its target. A slow off-rate indicates a long residence time of the drug on its target, which often correlates with prolonged pharmacological effects and higher in vivo potency. For many therapeutic antibodies, a slow off-rate is a key selection criterion, as it can lead to more durable target engagement and potentially less frequent dosing. Our affinity measurement services provide precise off-rate data to help you rank and select the most promising candidates.

Reference

Ma, Hui, Ciarán Ó'Fágáin, and Richard O'Kennedy. "Antibody stability: A key to performance-Analysis, influences and improvement." Biochimie 177 (2020): 213-225. https://doi.org/10.1016/j.biochi.2020.08.019

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.